170 related articles for article (PubMed ID: 25155290)
1. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
Gentzler RD; Yentz SE; Johnson ML; Rademaker AW; Patel JD
Cancer; 2014 Dec; 120(24):3853-8. PubMed ID: 25155290
[TBL] [Abstract][Full Text] [Related]
2. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
Ghimire S; Kyung E; Kim E
Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
[TBL] [Abstract][Full Text] [Related]
3. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
4. Shifting patterns in the interpretation of phase III clinical trial outcomes in advanced non-small-cell lung cancer: the bar is dropping.
Sacher AG; Le LW; Leighl NB
J Clin Oncol; 2014 May; 32(14):1407-11. PubMed ID: 24590634
[TBL] [Abstract][Full Text] [Related]
5. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
Brundage MD; Mackillop WJ
J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
[TBL] [Abstract][Full Text] [Related]
6. Age and treatment of non-small-cell lung cancer: a database analysis in elderly patients.
Berghmans T; Tragas G; Sculier JP
Support Care Cancer; 2002 Nov; 10(8):619-23. PubMed ID: 12436220
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
[TBL] [Abstract][Full Text] [Related]
8. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC.
Blumenschein GR; Reck M; Fossella F; Stewart DJ; Lathia C; Peña C
Cancer Biomark; 2011-2012; 10(6):287-98. PubMed ID: 22820084
[TBL] [Abstract][Full Text] [Related]
9. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
Langer F; Helsberg K; Schütte WH; Leschinger MI
Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
[TBL] [Abstract][Full Text] [Related]
10. Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges.
Pallis AG; Syrigos K
Cancer Treat Rev; 2012 Nov; 38(7):861-7. PubMed ID: 22217701
[TBL] [Abstract][Full Text] [Related]
11. Early-stage non-small-cell lung cancer: current perspectives in combined-modality therapy.
Bunn PA
Clin Lung Cancer; 2004 Sep; 6(2):85-98. PubMed ID: 15476594
[TBL] [Abstract][Full Text] [Related]
12. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors.
Griffioen GH; Toguri D; Dahele M; Warner A; de Haan PF; Rodrigues GB; Slotman BJ; Yaremko BP; Senan S; Palma DA
Lung Cancer; 2013 Oct; 82(1):95-102. PubMed ID: 23973202
[TBL] [Abstract][Full Text] [Related]
13. Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website.
Subramanian J; Madadi AR; Dandona M; Williams K; Morgensztern D; Govindan R
J Thorac Oncol; 2010 Aug; 5(8):1116-9. PubMed ID: 20592626
[TBL] [Abstract][Full Text] [Related]
14. Current treatment options for non-small-cell lung cancer.
Waxman ES
Oncology (Williston Park); 2012 Aug; 26(8 Suppl Nurse Ed):7-12. PubMed ID: 25375003
[TBL] [Abstract][Full Text] [Related]
15. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
Hotta K; Suzuki E; Di Maio M; Chiodini P; Fujiwara Y; Takigawa N; Ichihara E; Reck M; Manegold C; Pilz L; Hisamoto-Sato A; Tabata M; Tanimoto M; Shepherd FA; Kiura K
Lung Cancer; 2013 Jan; 79(1):20-6. PubMed ID: 23164554
[TBL] [Abstract][Full Text] [Related]
16. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
19. Current surgical treatment of non-small-cell lung cancer.
Van Schil PE; Hendriks JM; Hertoghs M; Lauwers P; Choong C
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1577-85. PubMed ID: 21999131
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer.
Xu YH; Lu S
Eur J Surg Oncol; 2014 Mar; 40(3):311-7. PubMed ID: 24332948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
